Efficacy of mesalazine at ulcerative colitis with nutritional failure
Abstract
Aim of investigation. To specify relation between trophological status, severity of relapse of ulcerative colitis (UC) and efficacy of 5-aminosalicylic acid (5-ASA) for achievement of clinical remission.
Summary. Nutritional status plays important role for body recovery at relapse of chronic diseases, including UC. At patients with nutritional failure remission achievement time becomes longer, bed-stay duration is increased. On the other hand, overweight patients often have more severe course of UC, as it affects important pathogenic processes. This article discusses possible links between trophological status and achievement of clinical remission, as well as between nutritional failure at UC and efficacy of mesalazine monotherapy.
Conclusion. More severe course of UC, long bedstay, lower mesalazine efficacy are marked at patients with nutritional failure in comparison with those scores at patients with normal trophological status. At over-weight patients in comparison with patients with normal nutritional status no significant differences in specified parameters is observed.
About the Authors
A. V. Korolyov
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Korolyov Aleksandr V — extramural post-graduate student, doctor of department of chronic bowel and pancreatic diseases
119991, Moscow, Pogodinskaya street, 1, bld 1
O. S. Shifrin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
MD, PhD head of department of chronic bowel and pancreatic diseases
119991, Moscow, Pogodinskaya street, 1, bld 1
O. Z. Okhlobystina
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
L. N. Androsova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Yu. O. Sidorina
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Хорошилов И. Е., Панов П. Б. Клиническая нутрициология / Под ред. А. В. Шаброва. СПб: ЭЛ-БИ-СПб, 2009:284.
2. Соботка Л. Материалы лекций для курсов Европейской ассоциации парентерального и энтерального питания. Петрозаводск: ИнтелТек, 2004.
3. Weerapan Khovidhunkit, Min-Sun Kim, Riaz A. Memon, et al. Effects of infection and inlamation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45:1169-90.
4. Щербакова Г. Н., Рагимов А. А. Энтеральное питание в многопрофильном стационаре: Учебное пособие для системы послевузовского профессионального образования врачей. 2-е изд., испр. и доп. М.: Практическая медицина, 2010:112.
5. Merli M., Riggio O., Dally L. Does malnutrition affect survival in cirrhosis? Hepatology 1996; 23(5):1041-6.
6. Mijač D.D., Janković G.L., Jorga J., Krstić M.N. Nutritional status in patients with active inflammatory bowel disease: Prevalence of malnutrition and methods for routine nutritional assessment. Eur J Intern Med 2010; 21(4):315-9.
7. Brooke C. Nutrition support in the compromised gut: Meeting the nutritional needs of the acute IBD patient. Liver & Intestinal Transplant Unit, Austin Health. AuSPEN ASM; Nov 2011.
8. Vadan R., Gheorghe L.S., Constantinescu A. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn’s disease treated with Infliximab. Clin Nutr 2011; 30(1):86-91.
9. Hartman C., Eliakim R., Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol 2009; 15(21):2570-8.
10. Boot A. M., Bouquetb J., Krenning E. P. Body composition versus bone mineral density in ulcerative colitis patients. Inflammatory bowel disease. Gut 1998; 42:188-94 doi:10.1136/gut.42.2.188.
11. Skowrońska-Piekarska U., Matysiak K., Sowińska A. The Impact of the nutritional state of patients on the results of the surgical treatment of ulcerative colitis. Pol J Surg 2013; 85(8), 424-32, ISSN (Print) 0032-373X, DOI:10.2478/pjs-2013-0065.
12. Greenbluma S., Turnbaughb P.J., Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease.
13. Allan Walker W. Obesity, innate immunity and gut inflammation. Curr Opin Gastroenterol 2007; 23(6):661-6.
14. Catalán V., Gómez-Ambrosi J., Rodríguez A., et al. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 2011; 17(11-12):1157-67. Published online 2011 July 5. doi:10.2119/molmed.2011.00144. PMCID: PMC3321803.
15. Peraldi P., Spiegelman B. TNF-alpha and insulin resistanse: summary and future prospects. Mol Cell Biochem 1998:169-71.
16. Mohamed-Ali V., Pinkney J. H., Coppack S. W. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22:1145-58.
17. Peyrin-Biroulet L., Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33(8):870-9.
18. Tessa E. H., Römkens M. D., Milou T., Kampschreur M. D., Joost P. H., Drenth M. D. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: Results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18(11):2190-8.
19. Geoffrey C. Nguyen M. D., PhD, FRCPC, Gilaad G., Kaplan M. D. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized Inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:1443-50; doi:10.1111 /j.1572-0241.2007.01780.
20. Bokemeyer B., Dignass A., Stijnen T., Veerman H. Higher remission rates in patients with once-daily dosing compared to twice-daily dosing: an analysis of compliance in the once-daily vs twice-daily podium trial with mesalazine (pentasa®) sachets. ECCO Congress, Hamburg, February 5-7, 2009.
21. Dignass А. U., Bokemeyer B., Stijnen T., Klugman T. Impact of once-daily versus twice-daily mesalazine (pentasa®) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial.
22. Poole C. D., Nielsen S. K., Currie C. J., Marteau P. Quality of life (health-related utility) in adults with ulcerative colitis in remission versus mild/moderate and severe relapse: findings from the podium study.
23. Flourie B., Hagege H., Tucat G., Maetz D. Randomised clinical trial: oncevs. twice-daily prolonged release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013; 37:767-75.
Review
For citations:
Korolyov A.V., Shifrin O.S., Okhlobystina O.Z., Androsova L.N., Sidorina Yu.O. Efficacy of mesalazine at ulcerative colitis with nutritional failure. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(1):37-42. (In Russ.)
Views:
102
Email this article 
